Table 6:
Characteristics of Prognostic Studies Evaluating MRD at End of Induction
| Author, Year | Country | Time Period | MRD Sample Size (Total) | ALL Type, % | Median Age, Years (Range) | Male, % | MRD Assay (Target) |
|---|---|---|---|---|---|---|---|
| Meleshko et al, 201167 | Belarus | 2003–2009 | 68 (279) | B-cell 78.0 T-cell 22.0 |
6.4 (1.4–22.8) | 55.9 | RQ-PCR (Ig/TCR) |
| Zhou et al, 200770 | United States, Canada | 1996–2000 | 284 (498) | B-cell | NR | 51.4 | RQ-PCR (Ig/TCR) |
| Laughton et al, 200566 | Australia | 1986–1998 | 62 (227) | B-cell 87.0 T-cell 10.0 Unknown 3.0 |
3.8 (1.3–15.9) | 38.1 | Real-time PCR (Ig/TCR) |
| Dworzak et al, 200264 | Austria | 1996–1998 | 108 (139) | B-cell 92.6 T-cell 7.4 |
3.8 (0.08–17.08) | 58.3 | FCM (LAIP) |
| Van Dongen et al, 199858 | Austria, Germany, Italy, Netherlands | 1991–1995 | 240 (625) | B-cell 87.5 T-cell 12.5 |
NR | NR | PCR (Ig/TCR) |
| Cavé et al, 199856,a | Belgium, France, Portugal | 1989–1996b | 178 (246) | B-cell 84 T-cell 16 |
NRc | NR | PCR (Ig/TCR) |
| Coustan-Smith et al, 1998, 200057,62,a | United States | 1991–1998 | 165 (195) | B-cell 71.5 T-cell 28.5 |
NRd | 64.2 | FCM (LAIP) |
Abbreviations: FCM, flow cytometry; Ig/TCR, immunoglobulin heavy chain or T-cell receptor gene rearrangements; LAIP, leukemia-associated immunophenotype; MRD, minimal residual disease; NR, not reported; PCR, polymerase chain reaction; RQ-PCR, real-time quantitative PCR.
a
Qualitative description of study only.
b
Recruitment at 1 centre from 1989 to 1996, and 10 additional centres from 1993 to 1996.
c
Median age and range not reported; however, participant age breakdown was as follows: 6% 0–1 year; 81% 2–9 years; 13% 10–15 years.
d
Median age and range not reported; however, participant age breakdown was as follows: 3.6% < 1 year; 63.0% 1–9; 33.4% >9 years.